Antiviral CD8 ؉ T cells are a key component of the adaptive immune system against hepatitis C virus (HCV).For the development of immune therapies, it is essential to understand how CD8 ؉ T cells contribute to clearance of infection and why they fail so often. A mechanism for secondary failure is mutational escape of the virus. However, some substitutions in viral epitopes are associated with fitness costs and often require compensatory mutations. We hypothesized that compensatory mutations may point toward epitopes under particularly strong selection pressure that may be beneficial for vaccine design because of a higher genetic barrier to escape. We previously identified two HLA-B*15-restricted CD8 ؉ epitopes in NS5B (LLRHHNMVY 2450-2458 and SQRQKKVTF 2466-2474 ), based on sequence analysis of a large HCV genotype 1b outbreak. Both epitopes are targeted in about 70% of HLA-B*15-positive individuals exposed to HCV. Reproducible selection of escape mutations was confirmed in an independent multicenter cohort in the present study. Interestingly, mutations were also selected in the epitope flanking region, suggesting that compensatory evolution may play a role. Covariation analysis of sequences from the database confirmed a significant association between escape mutations inside one of the epitopes (H2454R and M2456L) and substitutions in the epitope flanking region (S2439T and K2440Q). Functional analysis with the subgenomic replicon Con1 confirmed that the primary escape mutations impaired viral replication, while fitness was restored by the additional substitutions in the epitope flanking region. We concluded that selection of escape mutations inside an HLA-B*15 epitope requires secondary substitutions in the epitope flanking region that compensate for fitness costs.A ntiviral CD8 ϩ T cells are one of the key components of the adaptive immune system against hepatitis C virus (HCV). During acute infection, HCV-specific CD8 ϩ T cells are activated in the majority of patients (24, 38). Nevertheless, viral persistence is observed in 50 to 80% of patients. These patients with chronic HCV infection are at risk of progressive liver disease and liver cancer. For the development of immune therapies against HCV, it is essential to understand how CD8 ϩ T cells contribute to clearance of infection and why they fail so often. Different mechanisms for CD8 ϩ T cell failure have been described. The proposed mechanisms include primary failure by lack or impairment of priming of specific CD8 ϩ T cells upon HCV infection, as well as secondary failure after the initial priming (reviewed in reference 40). Studies of patients with acute HCV infection suggest that CD8 ϩ T cells are activated in most patients, irrespective of the outcome of infection (6), which supports an important role for secondary failure of HCV-specific CD8 ϩ T cells.Upon transition from acute to chronic HCV infection, the frequency of specific CD8 ϩ T cells declines (6). Moreover, CD8 ϩ T cells from patients with chronic HCV infection produce fewer cytokines and p...